The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06028386
Recruitment Status : Recruiting
First Posted : September 8, 2023
Last Update Posted : September 11, 2023
Sponsor:
Information provided by (Responsible Party):
Arch Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this clinical evaluation is to collect and compare outcomes data from patients with UT 1A diabetic foot ulcers treated with 510K FDA cleared, commercially available self-assembling peptide, AC5®Advanced Wound System, as compared to an advanced standard of care. Patient outcomes will be compared at the end of the study.

Condition or disease Intervention/treatment Phase
Non-healing Wound Diabetic Foot Ulcer Device: AC5® Advanced Wound System Device: Fibracol Plus Collagen Dressing Not Applicable

Detailed Description:

This study is a prospective, multi-center randomized controlled study designed to collect patient outcomes data for the treatment of diabetic foot ulcers. (DFU) All subjects will receive standard of care procedures (SOC) such as wound cleaning, appropriate sharp debridement, and appropriate offloading of the DFU (e.g., offloading Camboot or post op shoe with offloading/wound care insole).

Subjects will be randomized and receive treatments to either of the following arms:

Arm 1 - Subject will receive SOC that will include AC5® Advanced Wound System as an active synthetic cellular tissue product, covered with a non-adherent dressing plus an appropriate outer dressing to maintain moisture balance, then wrapped with stretch gauze and self-adherent wrap. AC5 will be applied weekly and outer dressings will be redressed, if necessary, using the allowed secondary dressings.

Arm 2 - Subject will receive SOC that will include Fibracol Plus collagen dressing as an active dressing. This will be followed with an appropriate outer dressing to maintain moisture balance, then wrapped with stretch gauze and self-adherent wrap as needed. Fibracol Plus will be applied 3 x a week and any outer dressings will be redressed, if necessary, using the allowed dressings.

The study involves two phases: Screening and Treatment.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Pilot Study Evaluating Wound Closure With the Application of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers
Actual Study Start Date : August 15, 2023
Estimated Primary Completion Date : April 30, 2024
Estimated Study Completion Date : August 30, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm 1-AC5® Advanced Wound System
The intervention in this arm is the application of a synthetic self assembling peptide matrix (AC5) to UT Grade 1A diabetic foot ulcers
 Device: AC5® Advanced Wound System
This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
Placebo Comparator: Arm2- Fibracol Plus Collagen dressing
The intervention in this arm is the application of collagen dressings to UT Grade 1A diabetic foot ulcers
 Device: Fibracol Plus Collagen Dressing
This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of wounds closed [ Time Frame: before or at 12 weeks ]
    100% epithelialization

  2. Change in wound area size [ Time Frame: from randomization through to end of study (at 12 weeks) for non-closed wounds ]
    Assess the percent change in wound area

  3. Days to complete wound closure [ Time Frame: before or at 12 weeks ]
    median and mean


Secondary Outcome Measures :
  1. Number of units used to achieve wound closure [ Time Frame: before or at 12 weeks ]
    number of units used

  2. Changes in quality of life [ Time Frame: before or at 12 weeks ]
    Pain, odor, itch intensity and activities of daily living are assessed before any ulcer manipulations. Subject will fill out the quality of life form which utilizes a numeric scale from 0 (minimum) to indicate no pain, no odor, no itch, normal activities of daily living -10 (maximum) to indicate worst possible pain, extremely strong odor, worst possible itch and not able to perform activities of daily living.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females aged 18 or older.
  2. Subject is willing to sign informed consent and participate in all procedures with follow up evaluations as necessary to complete the study.
  3. Study ulcer is diabetic in origin, located on the foot or below the malleolus with ulcer extending through the dermis but not into tendon, muscle or bone (UT Grade 1A).
  4. Study ulcer size is a minimum of 2 cm2 and maximum 25 cm2 after the run-in period.
  5. Study ulcer has been present for a minimum of 4 weeks before enrollment and less than 1 year old, with documented failure of prior treatment to heal the wound.
  6. Study ulcer has been offloaded for at least 14 days prior to randomization.
  7. A two-week run-in period will precede enrollment in the trial to document the indolent nature of the subjects selected; healing rate is not to be > 40% during this period.
  8. Subject does not exhibit clinical signs / symptoms of infection upon gross observation or have been diagnosed with an active infection at time of screening.
  9. Subject has adequate control of diabetes demonstrated by Hemoglobin A1c < 12% within 90 days of screening.

  10. Subject has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days of the first screening visit:

    • Dorsal transcutaneous oxygen measurements (TCOM) ≥ 30mmHg.
    • Ankle-Brachial Index with results of ≥ 0.8 and ≤ 1.5 or had past intervention.

Exclusion Criteria:

  1. Study ulcer wound surface is area greater than 25 cm2.
  2. Study ulcer has > 40% wound healing during the 14 days screening period.
  3. Subject has a known history of poor compliance with medical treatments.
  4. Subject is presently participating in another clinical trial.
  5. Subject has a known or suspected local malignancy to the Study diabetic ulcer, or systemic malignancy.
  6. Subject has been diagnosed with autoimmune connective tissues diseases.
  7. Subject has received graft material or topical growth factors on the study ulcer within the previous 30 days.
  8. Subject has received application of topical steroids on the study ulcer surface within the previous 30 days.
  9. Subject is pregnant or breast feeding.
  10. Subject is on dialysis.
  11. Subject is taking medications that are considered immune system modulators or cytotoxic chemotherapies.
  12. Subject cannot be on systemic antibiotics prior to randomization, however, during the treatment phase infection management may include systemic antibiotics if in conjunction with debridement.
  13. Subject has a known allergy to ingredients/components of AC5.
  14. Subject has osteomyelitis, and/or bony prominences present in the wound.
  15. Subject has ulcer probing to bone and tendon. (UT Grade II or III A-D).
  16. Subject is unable to comply with planned study procedures and treatments.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06028386


Contacts
Layout table for location contacts
Contact: Evelyn Quintin 6174312308 equintin@archtherapeutics.com
Contact: Terry Norchi, MD 800-937-9030 tnorchi@archtherapeutics.com

Locations
Layout table for location information
United States, North Carolina
Dr. Christopher Gauland Not yet recruiting
Greenville, North Carolina, United States, 27834
Contact: Christopher Gauland       chris@ecfanc.com   
United States, Ohio
Dr. Brock Liden Recruiting
Circleville, Ohio, United States, 44113
Contact: Brock Liden       dpmresearch@gmail.com   
Sponsors and Collaborators
Arch Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Brock Liden, DPM WAFL, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Arch Therapeutics
ClinicalTrials.gov Identifier: NCT06028386    
Other Study ID Numbers: CP-1003
First Posted: September 8, 2023    Key Record Dates
Last Update Posted: September 11, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Arch Therapeutics:
DFU
self-assembling peptide
chronic wounds
Synthetic matrix
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Wounds and Injuries
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
 Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases